Viibryd

Type: Product

Name: Viibryd

First reported 20 hours ago - Updated 20 hours ago - 1 reports

Carl Icahn

Long-Time Forest CEO to Retire

Forest Laboratories Inc. announced that Howard Solomon, its CEO for the last 36 years, will retire at the end of 2013. Solomon, 85, will step down as president and CEO on Dec. 31, and will resign as chairman at the time of the company's annual shareholder ... [Published Drug Discovery and Development - 20 hours ago]

Entities: Howard Solomon, David Solomon, Carl Icahn, Daliresp, Viibryd

First reported May 24 2013 - Updated May 24 2013 - 1 reports

FOREST LABORATORIES INC - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations

Forest Laboratories, Inc., (herein referred to as "the Company," "we" or "our") is a pharmaceutical company that develops, manufactures, and sells branded forms of ethical drug products, most of which require a physician's prescription. Our primary and ... [Published Pharmacy Choice - May 24 2013]

Entities: Research & Development, Namenda, Viibryd, Lexapro, Daliresp

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Forest Labs climbs as CEO announces retirement

NEW YORK -- Shares of Forest Laboratories Inc. rose to a year high Thursday after the drugmaker said Howard Solomon, its CEO for 36 years, will retire at the end of 2013.THE SPARK: Solomon, 85, will step down as president and CEO on Dec. 31, and will ... [Published CNBC - May 23 2013]

Entities: Howard Solomon, Forest Laboratories Inc, David Solomon

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Merck & Co Inc

Business Briefs: Merck and Forest Labs

Merck experimental insomnia drug suvorexant looks safe and is effective at helping patients fall asleep more quickly and to stay asleep, advisors to the FDA said yesterday. Panelists voted 13-3 that starting doses (15 mg in elderly and 20 mg in non-elderly) ... [Published Medical Marketing And Media - May 23 2013]

Entities: Forest Laboratories Inc, Howard Solomon, Merck & Co Inc

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Is There a Pill For That? Forest Labs’ Iffy Pipeline

Forest Labs (FRX) has launched several new products in the past two years – yet has demonstrated limited success in filling the earnings void created by the patent expiry for Lexapro, its erstwhile blockbuster antidepressant. Can a new generation of products ... [Published Yahoo! Finance - May 21 2013]

Entities: Forest Laboratories Inc, Viibryd, Howard Solomon, Antidepressant

First reported Feb 28 2013 - Updated Mar 01 2013 - 2 reports

Pharma Spent Less $$ Last Year To Promote Drugs

In 2012, more than $27 billion was spent by the pharmaceutical industry in the US to promote medicines, which amounted to an 8 percent drop from the previous year. Some things, however, stayed the same. The share of the top therapeutic classes by spending ... [Published Pharmalot - Mar 01 2013]

Entities: Drugs, gastrointestinal tract, Antidepressant

First reported Dec 27 2012 - Updated Dec 27 2012 - 1 reports

Forest Laboratories Inc

VIIBRYD (Vilazodone Hydrochloride) Tablet VIIBRYD (Vilazodone Hydrochloride) Kit [Forest Laboratories, Inc.]

Updated Date: Dec 27, 2012 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Dec 27 2012]

Entities: Vilazodone, Viibryd, Forest Laboratories Inc

Quotes

"We believe the news of Mr. Solomon's pending retirement as CEO and Chairman of FRX could be a catalyst for significant change in the company's strategy going forward" Abraham said in a report

Long-Time Forest CEO to Retire [Published Drug Discovery and Development - 20 hours ago]

...territories (see 'search coverage' below) Identifies patents covering molecule, formulation, process, use, combination and assay techniques (see "Patent Categories Identified ‘below) Patent identification, categorization and interpretation Grouped by patent family and assigned to development categories based on Interpretation of key aspects of the patent claims Manual filtration of patents not relevant to generic development Updated on a monthly basis, including changes to patent families, statuses, and litigation Enables fast analysis and verification by hyper-linking to crucial patent documents and national registers Patent Categories Identified:"

Drugs Market: Comprehensive Patent Search Analysis for Vemurafenib, Colesevelam, Rifaximin and mo ... [Published PRWeb - Feb 19 2013]

More Content

sort by: Date \| Relevance
Long-Time Forest CEO to Retire [Published Drug Discovery and Development - 20 hours ago]
FOREST LABORATORIES INC - 10-K - Management's D... [Published Pharmacy Choice - May 24 2013]
Forest Labs climbs as CEO announces retirement [Published CNBC - May 23 2013]
Business Briefs: Merck and Forest Labs [Published Medical Marketing And Media - May 23 2013]
Is There a Pill For That? Forest Labs’ Iffy Pip... [Published Yahoo! Finance - May 21 2013]
Pharma Spent Less $$ Last Year To Promote Drugs [Published Pharmalot - Mar 01 2013]
Cymbalta still tops in U.S. drug promotion list [Published Medad Blog - Feb 28 2013]
Drugs Market: Comprehensive Patent Search Analy... [Published PRWeb - Feb 19 2013]
Forest Laboratories Earnings Call Insights: Reb... [Published Wall St. Cheat Sheet - Jan 16 2013]
VIIBRYD (Vilazodone Hydrochloride) Tablet VIIBR... [Published DailyMed Drug Label Updates for the last seven ... - Dec 27 2012]

Blogs

sort by: Date \| Relevance
Pharma Spent Less $$ Last Year To Promote Drugs [Published Pharmalot - Mar 01 2013] In 2012, more than $27 billion was spent by the pharmaceutical industry in the US to promote medicines, which amounted to an 8 percent drop from the previous year. Some things, however, stayed the same. The share of the top therapeutic classes by spending ...
Cymbalta still tops in U.S. drug promotion list [Published Medad Blog - Feb 28 2013] The 10 most promoted drugs in the United States in 2012 were Cymbalta, Celebrex, Advair, Crestor, Pradaxa, Cialis, Bystolic, Symbicort, Viibryd, and Spiriva, according to Cegedim Strategic Data’s “2012 U.S . Pharmaceutical Spending Report.” Companies ...
Forest Laboratories Earnings Call Insights: Reb... [Published Wall St. Cheat Sheet - Jan 16 2013] Forest Laboratories, Inc. ( NYSE:FRX ) recently reported its third quarter earnings and discussed the following topics in its earnings conference call. Rebate Charges David Risinger – Morgan Stanley: I have a number of financial questions, but ...
VIIBRYD (Vilazodone Hydrochloride) Tablet VIIBR... [Published DailyMed Drug Label Updates for the last seven ... - Dec 27 2012] Updated Date: Dec 27, 2012 EST ...